DrugMonitor™ Anti-Briakinumab Antibody (VS-1224-YC221)

CAT#: VS-1224-YC221

Briakinumab is a human anti-IL-12 monoclonal antibody being developed for T-cell-driven autoimmune diseases, aiming at treating psoriasis, multiple sclerosis, Crohn's Disease, and other autoimmune and inflammatory disorders. The DrugMonitor™ Anti-Briakinumab Antibody (VS-1224-YC221) is an anti-drug antibody (ADA) against Briakinumab. This drug-based antibody is raised in mice immunized with the Briakinumab. The anti-Briakinumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Briakinumab in samples.

Specifications

  • Host Animal
  • Mouse
  • Specificity
  • Briakinumab
  • Target
  • Briakinumab
  • Immunogen
  • Briakinumab
  • Type
  • Mouse IgG
  • Species Reactivity
  • Human
  • Purity
  • >95%
  • Purification
  • Protein G
  • Applications
  • ELISA, PK/PD, ADA control
  • Format
  • Liquid
  • Concentration
  • Batch-dependent
  • Buffer
  • PBS, pH 7.4
  • Preservative
  • No preservatives
  • Storage
  • Store at 4°C for 1-2 weeks and at -20°C for 1 year. Avoid repeated freezing and thawing.
  • Generic name
  • Briakinumab
  • Drug Weight
  • 146500.0 Da
  • Formula
  • C₆₃₇₆H₉₈₇₄N₁₇₂₂O₁₉₉₂S₄₄
  • Related Disease
  • psoriasis, multiple sclerosis, Crohn's Disease, and other autoimmune and inflammatory disorders
REVIEWS AND Q&AS CITATIONS RESOURCES DOWNLOADS RELATED PRODUCTS
Inquiry
Navs

Customer Review

Submit a review or a question

There are currently no Customer reviews or questions for VS-1224-YC221. Click the button above to contact us or submit your feedback about this product.

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Article title:
DOI/PubMed URL:
Email:
Name:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Datasheet

MSDS

COA

Certificate of Analysis Lookup

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Lot Number:

See other products for "Briakinumab"

Anti-Human IL12+IL23 Recombinant Antibody (Briakinumab)
Recombinant monoclonal antibody to IL12+IL23. Briakinumab (ABT-874) is a human monoclonal antibody for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. Like ustekinumab, the antibody targets the interleukins 12 and 23.
Afuco™ Anti-IL12+IL23 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-103)
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IL12+IL23. It is a human monoclonal antibody for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. Like , the antibody targets the interleukins 12 and 23.
Specific Inquiry
Go to compare Add to compare

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Go to compare

Go to compare